These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26589388)

  • 1. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset.
    Berna F; Misdrahi D; Boyer L; Aouizerate B; Brunel L; Capdevielle D; Chereau I; Danion JM; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Lancon C; Mallet J; Rey R; Passerieux C; Schandrin A; Schurhoff F; Tronche AM; Urbach M; Vidailhet P; Llorca PM; Fond G;
    Schizophr Res; 2015 Dec; 169(1-3):255-261. PubMed ID: 26589388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.
    Fond G; Boyer L; Favez M; Brunel L; Aouizerate B; Berna F; Capdevielle D; Chereau I; Dorey JM; Dubertret C; Dubreucq ; Faget C; Gabayet F; Laouamri H; Lancon C; Le Strat Y; Misdrahi D; Rey R; Passerieux C; Schandrin A; Schurhoff F; Tronche AM; Urbach M; Vidalhet P; Llorca PM; Pelissolo A;
    Psychopharmacology (Berl); 2016 Feb; 233(4):571-8. PubMed ID: 26630993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.
    Fond G; Resseguier N; Schürhoff F; Godin O; Andrianarisoa M; Brunel L; Bulzacka E; Aouizerate B; Berna F; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Faget C; Gabayet F; Lançon C; Llorca PM; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Boyer L; Leboyer M;
    Eur Arch Psychiatry Clin Neurosci; 2018 Sep; 268(6):541-553. PubMed ID: 29127503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
    Kane JM; Barnes TR; Correll CU; Sachs G; Buckley P; Eudicone J; McQuade R; Tran QV; Pikalov A; Assunção-Talbott S
    J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
    Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use.
    Lévy E; Margolese HC; Annable L; Chouinard G
    Can J Psychiatry; 2004 Jun; 49(6):398-402. PubMed ID: 15283536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The 10-year findings from the FondaMental Academic Center of Expertise for Schizophrenia (FACE-SZ): Review and recommendations for clinical practice].
    Schürhoff F; Fond G; Berna F; Bulzacka E; Godin O; Boyer L; Misdrahi D; Andrianarisoa M; Brunel L; Coulon N; Aouizerate B; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Faget C; Gabayet F; Mallet J; Rey R; Lancon C; Passerieux C; Schandrin A; Urbach M; Vidailhet P; Leboyer M; Llorca PM;
    Encephale; 2019 Feb; 45(1):9-14. PubMed ID: 30327207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?
    Barnes M; Lawford BR; Burton SC; Heslop KR; Noble EP; Hausdorf K; Young RM
    Aust N Z J Psychiatry; 2006; 40(6-7):575-80. PubMed ID: 16756583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is akathisia associated with poor clinical response to antipsychotics during acute hospital treatment?
    Luthra V; Pinninti NR; Yoder K; Musthaq MS; Umapathy C; Levinson DF
    Gen Hosp Psychiatry; 2000; 22(4):276-80. PubMed ID: 10936635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic.
    Kumsa A; Agenagnew L; Alemu B; Girma S
    PLoS One; 2020; 15(7):e0235365. PubMed ID: 32614868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia.
    Cem Atbaşoglu E; Schultz SK; Andreasen NC
    J Neuropsychiatry Clin Neurosci; 2001; 13(3):336-41. PubMed ID: 11514639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort.
    Mallet J; Le Strat Y; Schürhoff F; Mazer N; Portalier C; Andrianarisoa M; Aouizerate B; Berna F; Brunel L; Capdevielle D; Chereau I; D'Amato T; Denizot H; Dubreucq J; Faget C; Gabayet F; Lançon C; Llorca PM; Misdrahi D; Rey R; Roux P; Schandrin A; Urbach M; Vidailhet P; Fond G; Dubertret C;
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):332-339. PubMed ID: 28663115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
    Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
    J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug-induced akathisia].
    van Harten PN
    Ned Tijdschr Geneeskd; 2002 Jan; 146(3):110-4. PubMed ID: 11826669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
    Huang CL; Hwang TJ; Chen YH; Huang GH; Hsieh MH; Chen HH; Hwu HG
    J Formos Med Assoc; 2015 May; 114(5):438-45. PubMed ID: 25791540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.